- Supera-CBD eased heat-related pain due to
inflammation quickly and provided long-lasting pain relief lasting
up to five hours
- Results suggest Supera-CBD may target
specific pain pathways, lessening the potential for side
effects
- MyMD was issued Japanese Patent No. 7293561
B2, covering Supera-CBD as a new molecular entity, in
pharmaceutical formulations, and for use in therapeutic
treatments
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD)
(“MyMD” or “the Company”), a clinical stage biopharmaceutical
company developing groundbreaking therapies for the treatment of
serious and debilitating autoimmune and inflammatory diseases,
today announced results from a preclinical study of its
investigational cannabinoid Supera-CBD™, a novel, synthetic,
non-toxic cannabidiol (CBD) analog. In the study, Supera-CBD
targeted and quickly reduced inflammatory pain within 60 minutes,
providing pain relief for up to five hours. Comparatively,
traditional CBD had no effect on this type of pain in the same
study.
“These preclinical results illustrate the potential of
Supera-CBD to alleviate acute inflammatory pain related to
injuries, burns, surgery, and flare-ups from chronic inflammatory
conditions such as diabetic neuropathy and shingles,” said Chris
Chapman, MD, president, director and chief medical officer, MyMD.
“Moreover, these are exciting findings in that the effect
demonstrated appears to be targeted, as Supera-CBD alleviated pain
due to heat but did not affect pain related to touch in the model
of inflammation. This may indicate the potential for fewer side
effects compared to traditional opioid pain treatments, without the
functional impairment due to numbness in affected areas.”
According to study researchers at a major academic center where
the study was conducted, the results indicate that Supera-CBD may
have an effect on the body’s TRPV1 pain system channels, which
control heat-related pain.1 Added Dr. Chapman, “By targeting the
TRPV1 channels, which these results indicate Supera-CBD may be
capable of, we have the potential to advance treatment in
inflammatory-related pain, an area of great patient need.”
Dr. Chapman also noted that it was very significant that the
“U.S. Department of Justice Drug Enforcement Administration (DEA)’s
scientific review concluded Supera-CBD will not be considered a
controlled substance or listed chemical under the Controlled
Substances Act (CSA) and its governing regulations or require
scheduling during development.”
Acute pain related to inflammation, burns, and nerve-related
pain affects countless individuals worldwide. The global market for
pain management was valued at around $36 billion in 2021 and is
expected to reach $52 billion by 2026.
About Supera-CBD Supera-CBD™ is a synthetic,
non-toxic cannabidiol (CBD) analog that is an 8000-times more
potent CB2 agonist than plant-based CBD. In addition to its
potential role in managing addiction, anxiety, chronic pain and
seizures, Supera-CBD has also been shown in preclinical studies to
have anti-inflammatory effects. Supera-CBD is a unique synthetic
analog of CBD whose structure has been modified to be CB2-receptor
selective. Studies to investigate Supera-CBD’s binding and affinity
to CB1 and CB2 receptors show that the compound had very low
affinity to CB1 and had a four-fold increase in binding to the CB2
receptor in comparison to CBD. Supera-CBD has completed
genotoxicity studies, and the company has initiated preclinical
pain studies in partnership with Johns Hopkins Medicine.
On June 20, 2023, MyMD was issued Japanese Patent No. 7293561
B2, covering Supera-CBD™ as a new molecular entity, in
pharmaceutical formulations, and for use in therapeutic treatments.
With this latest issuance, the Company now has 23 issued patents
worldwide protecting this drug product candidate, along with two
pending applications.
About MyMD Pharmaceuticals MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), is a clinical stage biopharma company
developing groundbreaking therapies for the treatment of serious
and debilitating autoimmune and inflammatory diseases. MyMD’s lead
clinical candidate, MYMD-1®, is an orally available
next-generation TNF-α inhibitor with the potential to transform the
way that TNF-α based diseases are treated. MYMD-1®, with its
small molecule design, improved safety profile and ability to cross
the blood brain barrier, has the promise to provide meaningful
therapeutic solutions to patients not served by current TNF-α
inhibitors and as a potential therapy for CNS-based inflammatory
and autoimmune diseases. The company has completed Phase 2 studies
of MYMD-1® for sarcopenia/frailty, a result of the aging
process, as well as early-stage trials for rheumatoid arthritis
(RA), with the potential to expand into other applications.
MyMD’s second therapeutic candidate is Supera-CBD, a novel,
synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times
more potent a CB2 agonist (activator) than plant-based CBD. In
addition to its potential role in managing addiction, anxiety,
chronic pain and seizures, Supera-CBD has also been shown to have
anti-inflammatory effects. For more information, visit
www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements This press release may contain forward-looking
statements. These forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause
actual results, performance, or achievements to be materially
different from any expected future results, performance, or
achievements. Forward-looking statements speak only as of the date
they are made and none of MyMD nor its affiliates assume any duty
to update forward-looking statements. Words such as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,”
“would’’ and other similar expressions are intended to identify
these forward-looking statements. Important factors that could
cause actual results to differ materially from those indicated by
such forward-looking statements include, without limitation: the
timing of, and MyMD’s ability to, obtain and maintain regulatory
approvals for clinical trials of MyMD’s pharmaceutical candidates;
the timing and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the COVID-19 pandemic or
similar public health emergencies on MyMD’s results of operations,
business plan and the global economy. A discussion of these and
other factors with respect to MyMD is set forth in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022,
filed by MyMD on March 31, 2023, as may be supplemented or amended
by the Company’s Quarterly Reports on Form 10-Q. Forward-looking
statements speak only as of the date they are made and MyMD
disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 Reference: TRPV1 is a non-selective cation channel; when it is
activated by capsaicin, sodium and calcium ions flowing through
TRPV1 into the cell to depolarize nociceptive neurons, leading to
action potential firing and finally the sensation of spiciness
(Caterina et al., 1997).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019338152/en/
Investor Contact: Robert Schatz (646) 421-9523
rschatz@mymd.com
Media Contact: Andrea Cohen Sam Brown, Inc. (917) 209
7163 andreacohen@sambrown.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
